6533b852fe1ef96bd12aabc1
RESEARCH PRODUCT
Reaction of the bone structure to methotrexate-Palacos flow y. Experimental investigations in animals.
L. RudigJ. RudigierE. DingeldeinJ. DegreifH. Wahligsubject
musculoskeletal diseasesmedicine.medical_specialtyBone and BonesFractures BoneMedicineAnimalsOrthopedics and Sports Medicineskin and connective tissue diseasesWound HealingOsteosynthesisbusiness.industryBone CementsGeneral MedicineBone cementSurgeryFracture Fixation IntramedullaryMethotrexateTolerabilityOrthopedic surgerySurgeryMethotrexateRabbitsPathological fracturesbusinessBone structuremedicine.drugdescription
With the combined osteosynthesis of pathological fractures in association with tumors and/or metastases in mind, E. Merck (Darmstadt, FRG) developed a bone cement containing a cytostatic agent, methotrexate-Palacos flow y (MTX-Pf). The animal-experimental study presented here investigates the tolerability of MTX-Pf in the femurs of rabbits with lateral comparison. In these investigations we used both the concentration of 0.63% MTX, as is currently used in standard clinical surgery, as well as a much higher concentration of 2.5% MTX. The histological sections were investigated using microradiographic methods and provided no indication of any significant differences between the femora with the MTX-Pf implantation and those into which standard Palacos flow y had been implanted.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1989-01-01 | Archives of orthopaedic and trauma surgery |